Free Trial
→ The Death of the Nasdaq? (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:FBLG

FibroBiologics Q1 2024 Earnings Report

FibroBiologics logo
$1.16 -0.08 (-6.45%)
Closing price 04:00 PM Eastern
Extended Trading
$1.15 -0.01 (-0.86%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

FibroBiologics EPS Results

Actual EPS
-$5.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q1 2024
Date
5/14/2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
5:25PM ET

Upcoming Earnings

FibroBiologics' Q2 2026 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

FibroBiologics' Q1 2024 Quarterly reportQuarterly report
(10-Q)

FibroBiologics Earnings Headlines

FibroBiologics CEO Issues Letter to Shareholders
May 5 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287694/0/en/fibrobiologics-ceo-issues-letter-to-shareholders.html
FibroBiologics (NASDAQ:FBLG) Receives Hold Rating from Maxim Group
May 5 at 3:36 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30759137
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software stocks two months before they crashed this year. Now, he's warning that one AI lab's breakthrough could CRASH the Nasdaq while igniting a $500 trillion wealth transfer. He's found a little-known $40 "pre-IPO backdoor" into the private startup behind this economic sea change.tc pixel
May 8 at 1:00 AM  |  Chaikin Analytics (Ad)
Maxim Group downgrades FibroBiologics (FBLG)
May 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/maxim-group-downgrades-fibrobiologics-fblg/ar-AA22nEic
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/04/3287105/0/en/fibrobiologics-reports-preclinical-data-showing-fibroblast-spheroids-may-actively-reprogram-the-burn-wound-environment-to-drive-healing-and-reduce-scarring.html
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study
May 4, 2026  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/exclusive-fibrobiologics-targets-2026-data-readout-after-trial-progress-for-diabetic-foot-ulcer-study/ar-AA22lTOd
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile
Earnings Tools